[
    [
        {
            "time": "",
            "original_text": "预告 | 早期临床、真实世界、质量管理…泰格医药11月活动精彩纷呈",
            "features": {
                "keywords": [
                    "泰格医药",
                    "早期临床",
                    "真实世界",
                    "质量管理",
                    "11月活动"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "预告 | 早期临床、真实世界、质量管理…泰格医药11月活动精彩纷呈",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "Aggregate of abrdn plc增持泰格医药(03347)40.13万股，每股作价约139.80港元",
            "features": {
                "keywords": [
                    "增持",
                    "泰格医药",
                    "abrdn plc",
                    "40.13万股",
                    "139.80港元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Aggregate of abrdn plc增持泰格医药(03347)40.13万股，每股作价约139.80港元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【行情】港股医药外包板块再度下挫，康龙化成(03759.HK)跌5.3%，泰格医药(03347.HK)跌3.7%，药明生物(02269.HK)跌3.3%",
            "features": {
                "keywords": [
                    "港股",
                    "医药外包",
                    "康龙化成",
                    "泰格医药",
                    "药明生物",
                    "下挫"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【行情】港股医药外包板块再度下挫，康龙化成(03759.HK)跌5.3%，泰格医药(03347.HK)跌3.7%，药明生物(02269.HK)跌3.3%",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "【权益变动】泰格医药(03347.HK)获Sands Capital Management, LLC增持73.67万股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "Sands Capital Management",
                    "增持",
                    "73.67万股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347.HK)获Sands Capital Management, LLC增持73.67万股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药行业：行业景气度延续",
            "features": {
                "keywords": [
                    "医药行业",
                    "景气度",
                    "延续"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业：行业景气度延续",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        }
    ]
]